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ABSTRACT
Rare multiple congenital malformations/developmental disorders are challenging in clinical diagnosis. The introduction 
of next-generation sequencing (NGS) has revolutionized this diagnostic by offering multigene panels or whole-exome 
sequencing. However, if there is no possibility to perform NGS or if we are facing prenatal ultrasound results, clinical diag-
nostics is even more difficult. For a selected group of congenital metabolic disorders, resulting from defects in cholesterol 
biosynthesis (called cholesterolopathies), application of gas chromatography-mass spectrometry (GS-MS) may provide or 
orientate diagnostics. The most common of these is Smith-Lemli-Opitz syndrome (SLOS), but in this publication, we also 
want to introduce other cholesterolopathies and draw attention to the possibility of non-invasive prenatal diagnosis of SLOS.
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INTRODUCTION
Cholesterol (cholest-5-en-3beta-ol) is a chemical com-
pound belonging to specific lipids called steroids, which 
common feature is the presence of a carbon skeleton, com-
posed of four coupled rings (steran) (Fig. 1). 
In the human body, it occurs in plasma, blood and tis-
sues in both free and fatty acid esterified forms. Endogenous 
cholesterol is mainly synthesized in the liver, intestines and 
skin, as well as in the central nervous system [1]. The hu-
man brain contains 23% of the cholesterol circulating in 
the body. Most of it is synthesized in oligodendrocytes 
and accumulated in myelinated axon sheaths, but it is also 
found in the cells of neurons and astrocytes. The blood-brain 
barrier prevents the penetration of cholesterol from the 
bloodstream, which excludes the regulation of cholesterol 
levels in the brain through supplementation [1].  The optimal 
amount of cholesterol in the human body is determined by 
the correct course of the process of its biosynthesis, which 
may be disturbed in discussed below syndromes.
Although the developing fetus attempts to synthesize 
cholesterol, in the first weeks of pregnancy, it uses mainly 
maternal cholesterol. Its transport through the membranes 
of the secondary yolk sac (during the first eight weeks 
of gestation), and later the placenta (when trophoblast 
takes over its nutritional role) to the fetal circulation, 
determines the proper development of the embryo and 
Figure 1. Cholesterol (C27H46O) with marked side groups (hydroxyl 
and methyl)
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the development of most organs. Cholesterol molecules 
collected by the embryo participate in signalling pathways 
crucial for embryonic development — they regulate the 
function of sonic hedgehog (SHH) proteins [2]. These pro-
teins determine the survival and migration of nerve cells 
and important nuclear receptors, such as the transcription 
factor for alpha-fetoprotein, which, by binding to DNA GATA 
sequences, enables the transcription of numerous genes 
involved in the development of crucial organs [3].
Congenital defects in enzymes of the cholesterol biosyn-
thesis pathway have recently emerged as significant causes 
of congenital anomalies. Patients with these metabolic dis-
eases present with different malformations that involve 
many organs and systems [4–6]. To date, nine disorders due 
to enzymatic defects in post-squalene cholesterol biosyn-
thesis have been identified (Fig. 2). These are:
1. Smith–Lemli–Opitz syndrome (SLOS, OMIM: 270400),
2. X-linked dominant chondrodysplasia punctata type 
2 (CDPX2, OMIM: 302960) and MEND (male EBP disorder 
with neurological defects; OMIM: 300960),
3. Congenital hemidysplasia with ichthyosiform erythro-
derma and limb defects syndrome (CHILD syndrome, 
OMIM: 308050),
4. Sterol-C4-methyloxidase-like deficiency (SC4MOL defi-
ciency, OMIM: 607545),
5. CK syndrome [named for the initials of the original 
proband] (OMIM: 300831),
6. Greenberg/HEM dysplasia (hydrops-ectopic calcifica-
tion-moth-eaten skeletal dysplasia, OMIM: 215140), (this 
phenotype is likely due to a laminopathy, but is usually 
discussed with inborn errors of cholesterol synthesis, 
see Table 1 for causative details), 
7. Antley–Bixler syndrome with ambiguous genitalia (cy-
tochrome P450 oxidoreductase deficiency, POR defi-
ciency, OMIM: 201750),
8. Desmosterolosis (OMIM: 602398),
9. Lathosterolosis (OMIM: 607330).
SMITH-LEMLI-OPITZ SYNDROME
The best-known among the listed diseases is 
Smith–Lemli–Opitz syndrome caused by a low activity of 
3β-hydroxysteroid-D7-reductase (7-dehydrocholesterol re-
ductase, DHCR7). Its role is to convert 7-dehydrocholesterol 
(7DHC) into cholesterol in the Kandutsch-Russell pathway 
and 7-dehydrodesmosterol into desmosterol in the Bloch 
pathway (Fig. 3). 
Desmosterol is mainly present in the brain [7]. SLOS, first 
described in 1964, is also the first multiple malformation 
syndrome attributed to an inborn error of sterol synthesis 
[8, 9]. The consequence of a malfunctioning enzyme is 
primarily the accumulation of 7-DHC in blood and tissue 
and probably 7-dehydrodesmosterol in the brain [10]. Be-
sides, acting in cells Δ7,Δ8-isomerase converts 7-dehy-
drocholesterol into 8-dehydrocholesterol, and ,similarly, 
7-dehydrodesmosterol in 8-dehydrodesmosterol) [11]. 
Studies have shown that patients with milder symptoms 
have normal cholesterol levels in the membranes of nerve 
cells, which is probably due to its local synthesis. At the 
same time, it seems that disease symptoms may also be 
caused by the accumulation of 7,8-dehydrodesmosterol 
or its oxidised metabolites [10].
Although its clinical presentation may vary, SLOS is 
usually characterized by prenatal and postnatal growth 
retardation, microcephaly, moderate to severe intellectual 
disability, and multiple major and minor malformations, 
including characteristic facial features, cleft palate, cardiac 
defects, postaxial polydactyly, 2–3 toe syndactyly, hypospa-
dias, and undervirilization of the genitalia in males [9, 12, 
personal observation]. There are also data suggesting 
higher intrauterine mortality of SLOS-affected fetuses [13]. 
The reported manifestations of Smith–Lemli–Opitz syn-
drome during the prenatal period (presented in Tab. 1) 
include, among others: intrauterine growth retardation 
[14, 15], low maternal unconjugated estriol (MSuE3) [16], 
or a combination of very rare congenital anomalies, such 
as ulnar hypoplasia, vertebral segmentation anomalies, 
congenital pulmonary adenomatoid malformation, fused 
lungs, laparoschisis, holomyelia, and hypothalamic hamar-
toma [17].
Figure 2. Part of the cholesterol biosynthesis pathway (modified from 
Nowaczyk MJM, Cunniff C. 2012. Smith–Lemli–Opitz syndrome and 
other disorders of cholesterol biosynthesis: An introduction. Am J 
Med Genet Part C Semin Med Genet 160C: 239–241).
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PRENATAL FINDINGS AND POSTNATAL 
PRESENTATION OF INBORN ERRORS OF 
CHOLESTEROL BIOSYNTHESIS
Except for Smith–Lemli–Opitz syndrome, other diseases 
with aberrant cholesterol biosynthesis are rarely diagnosed. 
Some of them, however, show phenotypic overlap with 
SLOS, e.g., lathosterolosis [18] or emopamil binding protein 
(EBP) deficiency in males [19]. Other disorders, e.g., HEM 
dysplasia, CHILD syndrome, or POR deficiency, may result 
in specific and somehow recognizable prenatal findings (as 
noted in Table 1). Since the detailed descriptions of the syn-
dromes mentioned above caused by congenital cholesterol 
biosynthesis defects have already been discussed in several 
publications [4, 5, 20–23] reiterating imaging findings in de-
tails here is beyond the scope of this manuscript. In Table 1 
we listed most significant clinical and detailed biochemical 
features that are indicative of specific syndromes caused 
by an inborn error in cholesterol biosynthesis, thus being 
helpful in prenatal evaluation of fetuses with specific devel-
opmental anomalies. 
Therefore, we believe that it is worth keeping this group 
of disorders in mind during prenatal evaluation. It allows 
ordering the proper biochemical and/or molecular diag-
nostic tests to establish the diagnosis, verify the carrier 
status in the couples, specifying the recurrence risk in sub-
sequent pregnancies in the family, as well as implementing 
adequate support for the child: with a high-cholesterol 
diet in Smith–Lemli–Opitz syndrome or, as reported just 
recently, with simvastatin in lathosterolosis [24] as soon as 
possible. For most rare diseases, including inborn errors of 
metabolism, before attempting to perform prenatal testing 
in at-risk families, it is essential to establish the diagnosis in 
the affected relatives or carrier status in the couples. Nev-
ertheless, as congenital errors of cholesterol biosynthesis 
may be associated with: a) abnormal ultrasound features 
(mentioned in Tab. 1), b) a gestational biochemical marker 
(such as low maternal serum unconjugated estriol, uE3; 
abnormal GC-MS results) it is possible, although challeng-
ing, to suspect such disorders in the course of a pregnancy, 
even without a previous index case in the family [18, 26]. 
LABORATORY DIAGNOSTICS OF INBORN 
ERRORS OF CHOLESTEROL BIOSYNTHESIS
Cholesterol precursors are specific biochemical markers 
of its biosynthesis. Hence their quantification in body fluids, 
amniotic fluid samples or tissues is useful for the diagnosis 
of cholesterol biosynthesis pathway disorders. The proper 
prenatal diagnosis of these syndromes is of great value 
both for the given family (giving a reliable recurrence risk 
and the possibility to perform prenatal or preimplantation 
diagnostics) and for scientific studies (by improving current 
knowledge on human developmental processes).
A rapid and reliable diagnosis may be established using 
gas chromatography-mass spectrometry (GC-MS). It has 
been developed and validated for quantitative analysis of 
five sterols: cholesterol, 7-dehydrocholesterol, desmosterol, 
lathosterol, and sitosterol in amniotic fluid and plasma [19]. 
Moreover, reliable prenatal diagnosis of Smith–Lemli–Opitz 
syndrome may be achieved in a rapid and non-invasive man-
ner by GC-MS analysis of a maternal urine sample [33, 34]. 
It is based on measurements of specific metabolites, 7-de-
hydropregnantriol and 8-dehydroestriol, that are definite 
markers for pregnancies with SLOS-affected fetuses. It is 
noteworthy that Smith–Lemli–Opitz syndrome is the only 
autosomal recessive (with 25% risk of recurrence), multiple 
congenital anomaly disorder where such (urine-based, 
biochemical) non-invasive and reliable prenatal diagnosis 
is available.
Years ago, Department of Biochemistry at CMHI intro-
duced three methods of analysis of SLOS-specific 7- and 
8-dehydrometabolites that detect their abnormal concen-
trations of fetal origin in pregnant women in a single sample 
of mother’s urine, in amniotic fluid and after birth in the 
child’s blood. The first one, as a non-invasive procedure, is 
clinically very attractive and of great practical value (per-
sonal observation). During the analysis the excretion of 
7 and 8-dehydropregnanetriol (7-,8-DHPT), pregnantriol 
(PT), pregnandiol (PD), estriol (E3) and 8-dehydroestriol (8-
-DHE3) is measured. In the urine of pregnant mothers, high 
excretion of 7- and 8-DHPT is observed in fetuses affected 
by SLOS [33] (Fig. 4). 
However, the highest diagnostic value of pregnancy 
affected by SLO syndrome is found in the 7-DHPT/PT and 
(8-DHE3)/E3 ratios [35]. Increased amounts of 7- and 8-dehy-
drometabolites of fetal steroid origin expressed in relation to 
naturally occurring estriol and pregnanetriol in the pregnant 
mother’s urine is a biochemical indicator of a genetic defect 
Figure 3. Graphs showing two ways of cholesterol biosynthesis and 
the most important metabolites of the Kandutsch-Russell (above) 
and Bloch (below) pathways. Involved enzymes are under the name 
of a chemical compound
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in the DHCR7 gene in the fetus. Morning urine samples of 
pregnant women taken between 13 and 24 weeks of gesta-
tion are preferred for analysis.
Another technique to detect DHCR7 deficiency in the 
fetus is the analysis of amniotic fluid metabolites, where 
7- and 8-dehydrocholesterol occurring in trace amounts in 
children without SLO syndrome are directly quantified. The 
same chemical compounds are determined in the child’s 
plasma after birth, and their concentration is 50–1000 times 
higher than the reference norm, which at low cholesterol is 
a high diagnostic value in SLO syndrome (Fig. 5).
For verification of biochemical results or in cases when 
prenatal samples are not useful for biochemical tests (bor-
derline normal results or lack of validation for specific 
markers), molecular analyses may be offered for prenatal 
detection of the discussed syndromes. They are based on 
DNA isolated from chorionic villus, amniotic fluid or rarely 
umbilical blood. Results of biochemical analysis of maternal 
urine, amniotic fluid and direct CVS analysis are available 
within 2 or 3 days. Molecular studies of cultured amniocytes 
or villus cells require 2 to 3 weeks to complete.
CONCLUSIONS
We hope that this article will provide readers with knowl-
edge about a group of disorders characterized by defects 
in cholesterol biosynthesis, thus increasing awareness in 
the medical community about their diagnosis, especially 
in the prenatal period with the application of non-invasive 
prenatal biochemical test (GC-MS analysis). The validated 
methodology allows for cheap (comparing to molecular 
Figure 4. GC/MS results of maternal urine sample in pregnancy; A. affected with Smith-Lemli-Opitz syndrome (note elevated 7- and 8-DHPT);  
B. healthy child
Figure 5. GC/MS of plasma sample from; A. patient affected with Smith-Lemli-Opitz syndrome (note elevated 7- and 8-DHC); B. healthy patients
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testing, including a panel of genes or exome sequenc-
ing), fast and reliable diagnosis of some of them. In Poland, 
it is offered at the Children’s Memorial Health Institute, De-
partment of Biochemistry, Radioimmunology and Experi-
mental Medicine. The details of samples and shipment for 
Smith-Lemli-Opitz syndrome testing are given in the table 
below. 
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